Global life sciences and diagnostics company Revvity joins Alderley Park to boost groundbreaking Genomics England collaboration

Revvity, a global life sciences and diagnostics group, has chosen Bruntwood SciTech’s Alderley Park as its newest UK hub.  

As part of plans for a nationwide expansion, the provider of products and services in translational multi-omics technologies, biomarker identification, imaging, screening, detection and diagnosis, will be joining a thriving community of over 250 innovative drug discovery, biotech, medcomms, diagnostics, AI, digital health and beauty tech businesses at the campus. 

The leading science and innovation campus by Bruntwood SciTech - the UK’s largest property platform dedicated to the growth of the innovation economy, is a joint venture between Bruntwood, L&G, and Greater Manchester Pension Fund, and has supported Revvity with providing flexible, highly specialist workspace infrastructure and collaborative facilitation. Offering a supportive, well-connected ecosystem, Alderley Park continues to appeal to businesses at every stage of their growth and fundraising journeys, whether they be start-ups, scaleups or large multinationals. 

Groundbreaking genomics research to take place at Alderley Park 

Revvity’s location to Alderley Park follows it securing a world-leading research collaboration with Genomics England on the Generation Study, in collaboration with NHS England. The groundbreaking research aims to screen up to 100,000 newborns, and will help inform decisions on using whole genome sequencing to screen for rare genetic conditions, advancing abilities for early detection.

Revvity selected Alderley Park to help support their work and take advantage of the campus’ world-class specialist workspace infrastructure, amenities and power resilience. Revvity will now  utilise almost 6,000 sq ft of custom designed and fitted CL2 open-plan lab space within its Mereside hub. It will also be accompanied with a state-of-the-art, latest generation backup generator to ensure security and continuity of their research. 

In addition to specialist lab facilities, Revvity will also benefit from exclusive access to Bruntwood SciTech’s shared science services and coworking lab at Alderley Park, alongside a full range of leading amenities and green spaces, including meeting rooms and breakout spaces, cafes, on-site gym, sports pitches, state-of-the-art cycle and shower hub, The Churchill Tree pub, and 232-seat auditorium.

Facilitating world changing collaborations  

Focused on advancing research and diagnostics through technology and partnerships, Revvity will be based alongside leading innovators and technology-focused firms at Alderley Park with opportunities for collaboration with forward-thinking companies such as Medicines Discovery Catapult, CellCentric, Globachem Discovery, global software developers SAP, and companies who are part of the Alderley Park Life Sciences Accelerator and Female Founders Incubator.

Revvity will also continue to strengthen its connectivity to the NHS via Bruntwood SciTech’s joint venture partnership with Manchester University NHS Foundation Trust (MFT) and gain direct access to research, collaborations, sample supplies, and direct introductions to clinicians. They will also benefit from Bruntwood SciTech’s growth support which offers access to highly-skilled talent, connections to capital and investment such as the GMC Life Science Fund by Praetura and Northern Gritstone, and regional and nationwide new connections, fuelling its future growth. They not only become part of the Alderley Park like-minded community, but have access to Bruntwood SciTech’s UK wide customer network of 1,100 innovation-led companies to support further collaboration.

Chris Hughes, managing director, North Europe at Revvity, said: “As our work with Genomics England enters an exciting new chapter, so do we. Our UK expansion is about more than simply establishing a presence, it’s about unlocking new opportunities for collaboration and innovation. 

“With access to world-class lab infrastructure and unrivalled connectivity to the NHS collaborators and industry peers, our new Alderley Park base will be central to supporting the delivery of the Generation Study as one of the study’s extraction and sequencing collaborators. The Generation Study will help enable earlier diagnoses and better outcomes for newborns, while supporting our broader mission to push the boundaries of what’s possible in healthcare.’

Mark Julian, Associate Commercial Director, Bruntwood SciTech, said: “Supporting the growth of pioneering innovation businesses is central to our mission at Alderley Park. By delivering state-of-the-art workspace, tailored to specialist needs of companies like Revvity - alongside access to investment, skilled talent and potential collaborators - we can help these market-leading innovators grow and thrive, creating jobs and economic value across Cheshire and Greater Manchester.

“Revvity’s decision to join Alderley Park at such a pivotal moment in its journey, is a clear endorsement of Alderley Park and our role in accelerating the UK’s innovation economy. By joining a thriving community of over 250 science, technology and innovation-led businesses, Revvity is perfectly placed to collaborate and make meaningful scientific advances. 

“We’re thrilled to support not only Revvity’s UK growth, but also its collaboration with Genomics England. Their presence will strengthen our network of health innovators and make real world impactful changes to science, with benefits that will be felt far beyond Alderley Park.”